文献速递淋巴瘤

复发/难治性非霍奇金淋巴瘤中格菲妥单抗的药效学与分子反应相关性

Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma.
PubMed 文献 · Blood Adv · 2022-01-01

本研究基于NP30179首次人体1期试验剂量递增部分,评估格菲妥单抗在复发/难治性B细胞非霍奇金淋巴瘤患者中的药效学、作用机制及与临床反应相关的生物标志物。结果显示格菲妥单抗可剂量依赖性诱导细胞因子、T细胞边缘化、增殖和活化;治疗前肿瘤活检基因表达分析提示TP53信号等肿瘤细胞内在因素与耐药相关,且可能与效应T细胞减少相互关联。

要点

  • 格菲妥单抗治疗可剂量依赖性诱导细胞因子及外周血T细胞边缘化、增殖和活化。
  • 治疗前肿瘤活检基因表达分析提示TP53信号等肿瘤细胞内在因素与格菲妥单抗耐药相关。
  • 耐药肿瘤中肿瘤细胞内在因素可能与效应T细胞谱减少相互关联,本身即为不良预后因素。

核心结论

  • 整合生物标志物分析提供了格菲妥单抗作用机制的临床证据,支持最佳生物学剂量选择,并将进一步指导临床开发。

研究设计与样本

  • 研究NP30179是一项首次人体1期试验,本文评估其剂量递增部分患者样本中的生物标志物。
  • 患者接受单剂奥妥珠单抗预处理1000 mg,7天后静脉给予格菲妥单抗5 µg至25 mg。
  • 格菲妥单抗治疗最长12个周期,每2或3周一次。

主要发现

  • 格菲妥单抗治疗观察到药效学调节,包括剂量依赖性诱导细胞因子以及外周血T细胞边缘化、增殖和活化。
  • 治疗前肿瘤活检样本基因表达分析表明,TP53信号等肿瘤细胞内在因素与格菲妥单抗耐药相关。
  • 耐药肿瘤中肿瘤细胞内在因素可能与效应T细胞谱减少相互关联,本身即为不良预后因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glofitamab, a novel CD20xCD3, T-cell-engaging bispecific antibody, exhibited single-agent activity in Study NP30179, a first-in-human, phase 1 trial in relapsed/refractory B-cell non-Hodgkin lymphoma. Preclinical studies showed that glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Here, we provide evidence of glofitamab's clinical activity, including pharmacodynamic profile, mode of action, and factors associated with clinical response, by evaluating biomarkers in patient samples from the dose-escalation part of this trial. Patients enrolled in Study NP30179 received single-dose obinutuzumab pretreatment (1000 mg) 7 days before IV glofitamab (5 µg-25 mg). Glofitamab treatment lasted ≤12 cycles once every 2 or 3 weeks. Blood samples were collected at predefined time points per the clinical protocol; T-cell populations were evaluated centrally by flow cytometry, and cytokine profiles were analyzed. Immunohistochemical and genomic biomarker analyses were performed on tumor biopsy samples. Pharmacodynamic modulation was observed with glofitamab treatment, including dose-dependent induction of cytokines, and T-cell margination, proliferation, and activation in peripheral blood. Gene expression analysis of pretreatment tumor biopsy samples indicated that tumor cell intrinsic factors such as TP53 signaling are associated with resistance to glofitamab, but they may also be interlinked with a diminished effector T-cell profile in resistant tumors and thus represent a poor prognostic factor per se. This integrative biomarker data analysis provides clinical evidence regarding glofitamab's mode of action, supports optimal biological dose selection, and will further guide clinical development. This trial was registered at www.clinicaltrials.gov as #NCT03075696.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bröske AE, Korfi K, Belousov A, et al. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma. Blood Adv. 2022. PMID: 34941996. doi:10.1182/bloodadvances.2021005954

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。